Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Assets (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Other Non-Current Assets data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 2841.18% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 2841.18%, while the annual FY2025 figure was $2.0 million, 2841.18% up from the prior year.
  • Other Non-Current Assets reached $2.0 million in Q4 2025 per FHTX's latest filing, roughly flat from $2.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.4 million in Q1 2022 and bottomed at $24000.0 in Q1 2025.
  • Average Other Non-Current Assets over 5 years is $1.6 million, with a median of $1.7 million recorded in 2021.
  • The widest YoY moves for Other Non-Current Assets: up 2841.18% in 2025, down 98.59% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $2.4 million in 2021, then fell by 0.88% to $2.4 million in 2022, then tumbled by 53.13% to $1.1 million in 2023, then plummeted by 93.9% to $68000.0 in 2024, then skyrocketed by 2841.18% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.